Developing Cellular Therapies for Stroke

Savitz, Sean I

doi:10.1161/strokeaha.115.007149

Cited by 39 publications

(28 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Cellular therapy is another investigative modality that offers considerable hope and promise to promote post stroke recovery. 4 …”

Section: Introductionmentioning

confidence: 99%

Systematic Review and Meta-Analysis of Bone Marrow–Derived Mononuclear Cells in Animal Models of Ischemic Stroke

Vahidy¹,

Rahbar²,

Zhu³

et al. 2016

Stroke

Self Cite

View full text Add to dashboard Cite

Background and Purpose Bone marrow derived mononuclear cells (BMMNCs) offer the promise of augmenting post-stroke recovery. There is mounting evidence of safety and efficacy of BMMNCs from pre-clinical studies of ischemic stroke (IS), however their pooled effects have not been described. Methods Using PRIMSA guidelines, we conducted a systematic review of pre-clinical literature for intravenous use of BMMNCs followed by meta-analyses of histological and behavioral outcomes. Studies were selected based on pre-defined criteria. Data were abstracted by two independent investigators. Following quality assessment, the pooled effects were generated using mixed effect models. Impact of possible biases on estimated effect size was evaluated. Results Standardized mean difference (SMD), 95% confidence interval (CI) for reduction in lesion volume was significantly beneficial for BMMNC treatment (SMD −3.3, 95% CI: −4.3, −2.3), n = 113 each for BMMNC and controls. BMMNC treated animals (n = 161) also had improved function measured by cylinder test (SMD −2.4, 95% CI: −3.1, −1.6), as compared to controls (n = 205). A trend for benefit was observed for adhesive removal test and neurological deficit score. Study quality score (median: 6, Q1-Q3: 5-7) was correlated with year of publication. There was funnel plot asymmetry, however the pooled effects were robust to the correction of this bias and remained significant in favor of BMMNC treatment. Conclusions BMMNCs demonstrate beneficial effects across histological and behavioral outcomes in animal IS models. Though study quality has improved over time, considerable degree of heterogeneity calls for standardization in the conduct and reporting of experimentation.

show abstract

“…3 Cellular therapy is another investigative modality that offers considerable hope and promise to promote post stroke recovery. 4 …”

Section: Introductionmentioning

confidence: 99%

Systematic Review and Meta-Analysis of Bone Marrow–Derived Mononuclear Cells in Animal Models of Ischemic Stroke

Vahidy¹,

Rahbar²,

Zhu³

et al. 2016

Stroke

Self Cite

View full text Add to dashboard Cite

show abstract

“…Aslında bu tedavilerde sadece kök hücreler değil, olgun hücreler de kullanıldığı için "kök hücre tedavisi" yerine "hücresel tedavi" demek daha uygundur (1 (8,9).…”

Section: Hücresel Tedavi̇unclassified

Stem Cell Therapies in Ischemic Stroke

İnce¹

2017

Türk Beyin Damar Hast Derg

View full text Add to dashboard Cite

“…[91] In the last well suited for acute stroke treatment, because MNCs can be harvested from the bone marrow within hours and can be immediately reinfused without culture. [100] The feasibility and safety of intravenous MNCs for the treatment of acute ischemic stroke has already been confirmed in a clinical feasibility study.…”

Section: Cell Therapiesmentioning

confidence: 99%

Promoting recovery from ischemic stroke

Schmidt

Minnerup

2016

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Over recent decades, experimental and clinical stroke studies have identified a number of neurorestorative treatments that stimulate neural plasticity and promote functional recovery. In contrast to the acute stroke treatments thrombolysis and endovascular thrombectomy, neurorestorative treatments are still effective when initiated days after stroke onset, which makes them applicable to virtually all stroke patients. In this article, selected physical, pharmacological and cell-based neurorestorative therapies are discussed, with special emphasis on interventions that have already been transferred from the laboratory to the clinical setting. We explain molecular and structural processes that promote neural plasticity, discuss potential limitations of neurorestorative treatments, and offer a speculative viewpoint on how neurorestorative treatments will evolve.

show abstract

Developing Cellular Therapies for Stroke

Cited by 39 publications

References 48 publications

Systematic Review and Meta-Analysis of Bone Marrow–Derived Mononuclear Cells in Animal Models of Ischemic Stroke

Systematic Review and Meta-Analysis of Bone Marrow–Derived Mononuclear Cells in Animal Models of Ischemic Stroke

Stem Cell Therapies in Ischemic Stroke

Promoting recovery from ischemic stroke

Contact Info

Product

Resources

About